サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1560967

バイオサージェリー市場レポート：製品、由来、用途、エンドユーザー、地域別、2024年～2032年

Biosurgery Market Report by Product, Source, Application, End User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 146 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
バイオサージェリー市場レポート：製品、由来、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のバイオサージェリー市場の市場規模は2023年に139億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに241億米ドルに達し、2024年から2032年の間に6.1％の成長率（CAGR）を示すと予測しています。この市場を牽引しているのは、外科手術の増加、医療機器の技術進歩、複雑な手術における効果的な創傷管理に対する需要の高まりであり、これにより世界中の患者の手術成績と回復時間が向上しています。

バイオサージェリー市場分析：

  • 主な市場促進要因：慢性疾患の増加や高齢化は、高度な外科手術や創傷ケアソリューションを必要とするため、バイオサージェリー市場の主要な促進要因となっています。さらに、生体材料や手術手技の技術的進歩も、外科手術の有効性と安全性を高めることで市場の成長を促進しています。
  • 主な市場動向：低侵襲性外科手術への傾向が強まっており、迅速な回復と術後合併症の軽減をサポートする生物外科製品への需要が高まっています。また、個別化医療や標的療法への注目の高まりが、個々の患者のニーズに合わせた生物外科製品の開発に影響を与えています。
  • 地理的動向：北米は高度なヘルスケア・インフラと新技術の採用率の高さから、バイオサージェリー市場で大きなシェアを占めています。また、アジア太平洋市場は、ヘルスケア投資の増加、認知度の向上、患者人口の増加により急成長を遂げています。
  • 競合情勢：バイオサージェリーの主要企業としては、B. Braun Melsungen AG、Baxter International Inc.、Becton Dickinson and Company、CryoLife Inc.、CSL Limited、Hemostasis LLC、Integra Lifesciences Holdings Corporation、Johnson &Johnson、Medtronic plc、Pfizer Inc.、Sanofi S.A.、Smith &Nephew plc、Stryker Corporation、Surgalign Spine Technologies Inc.などが挙げられます。
  • 課題と機会：バイオサージェリー市場における主な課題は、先進的な生物外科製品のコストが高いことであり、コストに敏感な地域では導入が制限される可能性があります。さらに、コスト効率の高いソリューションを開発し、新興国市場に進出する大きな機会があり、そこでは医療水準の向上が新たな成長の可能性をもたらしています。

バイオサージェリー市場傾向：

手術件数の増加

世界の外科手術の一貫した増加は、バイオサージェリー市場に大きな影響を与えています。米国国立衛生研究所（NIH）の統計で報告されているように、2017年に980万件の主要な入院患者外科手術を分析した結果、11.1％が低侵襲手術（MIS）を、2.5％がロボット支援を利用していることが明らかになった。これは、2018年に実施された960万件の入院患者手術と比較すると、11.2％がMIS、2.9％がロボット支援でした。さらに、外来MIS手術の割合も年々増加し、2016年の16.9％から2018年には18％となった。この増加は、医療技術と手術手技の進歩により、手術がより安全で身近なものになったことが主な要因です。人口の高齢化と生活の質の向上への関心の高まりが、この増加に寄与しています。手術件数の増加に伴い、合併症の軽減と治療成績の向上に不可欠なバイオサージェリー製品の需要も増加しています。シーラント、止血剤、接着剤などの製品は、術後の回復を確実にし、術中のリスクを最小限に抑えるためにますます使用されるようになり、バイオサージェリー市場の見通しを明るいものにしています。

慢性疾患の増加

心血管疾患、糖尿病、がんなどの慢性疾患の蔓延は、バイオサージェリー市場のもう一つの重要な促進要因です。米国疾病管理予防センターは、米国成人の60％が少なくとも1つの慢性疾患に罹患しており、その多くが外科的介入を必要としていると指摘しています。全米慢性疾患担当者協会によると、CDCは、米国における年間3兆8,000億米ドルのヘルスケア支出の90%は、慢性疾患や精神的な健康状態に関連したものであると報告しています。例えば、心臓病と脳卒中は米国における主要な死因であり、年間94万4,800人以上の命を奪っており、全死亡者の3分の1以上を占めています。さらに、心血管疾患に関連する費用は2050年までに2兆ドルに達すると予測されています。さらに、外科的介入には、特に複雑な手術において、出血を管理し、組織を修復し、治癒を促進するために、しばしばバイオサージェリー製品が使用されます。慢性疾患の罹患率が増加の一途をたどる中、革新的なバイオサージェリー・ソリューションに対する需要はますます高まっており、企業には複雑な医療ニーズに対応する技術の開発と改良を促し、その結果、バイオサージェリー市場全体の収益を増加させています。

スポーツ傷害の発生率の上昇

スポーツ参加者の増加や身体活動への熱意は、スポーツ関連傷害の発生率の上昇につながっており、これがバイオサージェリー市場の価値にさらなる影響を与えています。ジョン・ホプキンス医学の報告によると、米国では毎年350万人以上のスポーツ傷害が発生しています。スポーツやレクリエーション活動による頭部外傷のほぼ50％は、自転車、スケートボード、スケート靴によるものです。また、15歳未満の子供のうち、年間77万5,000人以上がスポーツ関連の怪我で救急外来を受診しています。これらの怪我は、非公式のスポーツイベントやレクリエーション運動会での転倒、衝突、過労が原因であることが多いです。また、靭帯断裂や関節脱臼など、いくつかのスポーツ外傷では、迅速かつ効率的な回復を促すために、バイオサージェリー製品を使用した外科手術が必要となります。さらに、スポーツ医学においても、これらの製品は回復を早め、選手をベストな状態に戻すために不可欠です。スポーツへの関心がアマチュアやプロのレベルで高まり続ける中、外科的介入を必要とする怪我の頻度は、この分野におけるスポーツ関連の治療用に特別に設計されたバイオサージェリー機器への需要を増大させると思われます。

本レポートで扱う主な質問

  • 世界のバイオサージェリー市場はこれまでどのように推移してきたか？
  • バイオサージェリー市場の世界における促進要因、抑制要因、機会は何か？
  • 促進要因、抑制要因、機会が世界のバイオサージェリー市場に与える影響は？
  • 主要地域市場とは？
  • 最も魅力的なバイオサージェリー市場はどの国か？
  • 製品別の市場内訳は？
  • バイオサージェリー市場で最も魅力的な製品は？
  • 市場内訳の源泉は？
  • バイオサージェリー市場で最も魅力的なソースは？
  • アプリケーション別の市場内訳は？
  • バイオサージェリー市場で最も魅力的なアプリケーションは？
  • エンドユーザー別の市場内訳は？
  • バイオサージェリー市場で最も魅力的なエンドユーザーは？
  • 市場の競合構造は？
  • 世界のバイオサージェリー市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のバイオサージェリー市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 骨移植代替品
    • 市場動向
    • 市場予測
  • 軟部組織アタッチメント
    • 市場動向
    • 市場予測
  • 止血剤
    • 市場動向
    • 市場予測
  • 外科用シーラントおよび接着剤
    • 市場動向
    • 市場予測
  • 癒着防止バリア
    • 市場動向
    • 市場予測
  • ステープルライン補強
    • 市場動向
    • 市場予測

第7章 市場内訳：出典

  • 天然/生物由来製品
    • 市場動向
    • 市場予測
  • 合成製品
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 整形外科
    • 市場動向
    • 市場予測
  • 一般外科
    • 市場動向
    • 市場予測
  • 神経外科
    • 市場動向
    • 市場予測
  • 心臓血管外科
    • 市場動向
    • 市場予測
  • 婦人科手術
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton Dickinson and Company
    • CryoLife Inc.
    • CSL Limited
    • Hemostasis LLC
    • Integra Lifesciences Holdings Corporation
    • Johnson & Johnson
    • Medtronic plc
    • Pfizer Inc.
    • Sanofi S.A.
    • Smith & Nephew plc
    • Stryker Corporation
    • Surgalign Spine Technologies Inc.
図表

List of Figures

  • Figure 1: Global: Biosurgery Market: Major Drivers and Challenges
  • Figure 2: Global: Biosurgery Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biosurgery Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biosurgery Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Biosurgery Market: Breakup by Source (in %), 2023
  • Figure 6: Global: Biosurgery Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Biosurgery Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Biosurgery Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Biosurgery (Bone-Graft Substitutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Biosurgery (Bone-Graft Substitutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Biosurgery (Soft-Tissue Attachments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Biosurgery (Soft-Tissue Attachments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Biosurgery (Hemostatic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Biosurgery (Hemostatic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Biosurgery (Surgical Sealants and Adhesives) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Biosurgery (Surgical Sealants and Adhesives) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Biosurgery (Adhesion Barriers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Biosurgery (Adhesion Barriers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Biosurgery (Staple Line Reinforcement) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Biosurgery (Staple Line Reinforcement) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Biosurgery (Natural/Biologics Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Biosurgery (Natural/Biologics Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Biosurgery (Synthetic Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Biosurgery (Synthetic Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Biosurgery (Orthopedic Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Biosurgery (Orthopedic Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Biosurgery (General Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Biosurgery (General Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Biosurgery (Neurological Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Biosurgery (Neurological Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Biosurgery (Cardiovascular Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Biosurgery (Cardiovascular Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Biosurgery (Gynecological Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Biosurgery (Gynecological Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Biosurgery (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Biosurgery (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Biosurgery (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Biosurgery (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Biosurgery (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Biosurgery (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Biosurgery (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Biosurgery (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Biosurgery Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Biosurgery Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Biosurgery Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Biosurgery Industry: SWOT Analysis
  • Figure 93: Global: Biosurgery Industry: Value Chain Analysis
  • Figure 94: Global: Biosurgery Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biosurgery Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Biosurgery Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Biosurgery Market Forecast: Breakup by Source (in Million US$), 2024-2032
  • Table 4: Global: Biosurgery Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Biosurgery Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Biosurgery Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Biosurgery Market: Competitive Structure
  • Table 8: Global: Biosurgery Market: Key Players
目次
Product Code: SR112024A4522

The global biosurgery market size reached US$ 13.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.1 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032. The market is driven by the increasing surgical procedures, technological advancements in medical devices, and growing demand for effective wound management in complex surgeries, which is enhancing surgical outcomes and recovery times for patients across the globe.

Biosurgery Market Analysis:

  • Major Market Drivers: The increasing prevalence of chronic diseases and the aging population are major drivers for the biosurgery market, as they necessitate advanced surgical interventions and wound care solutions. Moreover, technological advancements in biomaterials and surgical techniques are also driving market growth by enhancing the effectiveness and safety of surgical procedures.
  • Key Market Trends: There is a growing trend toward minimally invasive surgical procedures, which is escalating the demand for biosurgical products that support quick recovery and reduced post-operative complications. Besides, increased focus on personalized medicine and targeted therapies are influencing the development of biosurgical products tailored to individual patient needs.
  • Geographical Trends: North America holds a significant share of the biosurgery market due to its advanced healthcare infrastructure and high adoption rates of new technologies. Moreover, the markets in Asia-Pacific are experiencing rapid growth due to rising healthcare investments, increasing awareness, and a growing patient population.
  • Competitive Landscape: Some of the leading biosurgery companies include B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc., among many others.
  • Challenges and Opportunities: The major challenge in the biosurgery market is the high cost of advanced biosurgical products, which can limit adoption in cost-sensitive regions. Moreover, there are significant opportunities for developing cost-effective solutions and expanding into emerging markets, where rising healthcare standards present new growth potential.

Biosurgery Market Trends:

The Growing Number of Surgical Procedures

The consistent increase in surgical procedures globally significantly impacts the biosurgery market. As reported by the National Institutes of Health (NIH) statistics, in 2017, an analysis of 9.8 million major inpatient surgical procedures revealed that 11.1% involved minimally invasive surgery (MIS) and 2.5% utilized robotic assistance. This compares to the 9.6 million inpatient surgeries performed in 2018, where 11.2% were MIS and 2.9% were robotic assisted. Additionally, the percentage of ambulatory MIS procedures also grew annually, from 16.9% in 2016 to 18% in 2018.. This uptick is largely driven by advancements in medical technology and surgical techniques, which have made surgeries safer and more accessible. An aging population and a greater focus on enhancing quality of life contribute to this increase. As surgical volumes grow, the demand for biosurgery products, essential for reducing complications and improving outcomes, also increases. Products such as sealants, hemostatic agents, and adhesives are increasingly used to ensure better recovery and minimize intraoperative risks, thereby creating a positive biosurgery market outlook.

Increase in Chronic Diseases

The escalating prevalence of chronic diseases such as cardiovascular conditions, diabetes, and cancer is another pivotal driver for the biosurgery market. The Centers for Disease Control and Prevention notes that 60% of U.S. adults suffer from at least one chronic disease, many of which necessitate surgical interventions. According to the National Association of Chronic Disease Directors, the CDC reports that 90% of the annual $3.8 Trillion healthcare expenditure in the U.S. is linked to individuals with chronic illnesses and mental health conditions. For instance, heart disease and stroke are the leading causes of death in the United States, claiming over 944,800 lives annually, which accounts for more than one-third of all deaths. Furthermore, it is projected that the costs associated with cardiovascular diseases will reach $2 Trillion by 2050. Additionally, surgical interventions often include the use of biosurgery products to manage blood loss, repair tissues, and promote healing, particularly in complex procedures. As the incidence of chronic diseases continues to increase, the demand for innovative biosurgery solutions intensifies, encouraging companies to develop and refine technologies that cater to complex medical needs, thus increasing the overall biosurgery market revenue.

Rising Incidence of Sports Injuries

The increase in sports participation and enthusiasm for physical activities has led to a higher incidence of sports-related injuries, which is further influencing the biosurgery market value. According to a John Hopkins Medicine report, in the United States (US) over 3.5 million sports injuries occur each year. Almost 50% of all head injuries from sports or recreational activities are the result of incidents involving bicycles, skateboards, or skates. In addition, more than 775,000 kids under the age of 15 seek care for sports-related injuries in emergency departments yearly. These injuries frequently result from falls, collisions, and overexertion during unofficial sporting events or recreational athletic events. Besides, several sports injuries, including ligament rips and joint dislocations, need surgical procedures that use biosurgery products to promote a speedy and efficient recovery. Moreover, in sports medicine, these products are essential for accelerating recovery and getting players back to their best. As interest in sports continues to grow at amateur and professional levels, the frequency of injuries requiring surgical intervention will increase demand for biosurgery devices specifically designed for sports-related treatments in this sector.

Biosurgery Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, source, application and end user.

Breakup by Product:

  • Bone-Graft Substitutes
  • Soft-Tissue Attachments
  • Hemostatic Agents
  • Surgical Sealants and Adhesives
  • Adhesion Barriers
  • Staple Line Reinforcement

Bone-graft substitutes account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple line reinforcement. According to the report, bone-graft substitutes represented the largest segment.

Bone-graft substitutes are crucial alternatives to bone grafting. These stand-ins play a critical role in many surgical operations, supporting bone regeneration and repair in orthopedics, trauma, spine surgery, and dentistry applications. They are intended to minimize the risk of donor site morbidity and infection by promoting bone development and replacing conventional autografts, which require removing bone from the patient's own body. Furthermore, the expansion is driven by the increasing frequency of bone and joint problems, the need for less intrusive operations, and developments in biomaterial technology. The growth of this market segment is also fueled by the creation of novel synthetic and composite grafts with improved osteoconductive and osteoinductive qualities. For instance, on 23 May 2023, Royal Biologics, Inc., a company focused on advanced cellular and autologous technologies for improved surgical outcomes, unveiled BIO-REIGN 3D. This innovative bone graft substitute is the first to use a natural hyper-crosslinked carbohydrate polymer. It is designed to enhance bone grafting procedures, and this proprietary technology is introduced alongside Royal Biologics' licensing agreement for Molecular Matrix's patented Osteo-P BGS technology.

Breakup by Source:

  • Natural/Biologics Products
  • Synthetic Products

Natural/biologics products hold the largest share of the industry

A detailed breakup and analysis of the market based on the source have also been provided in the report. This includes natural/biologics products and synthetic products. According to the report, natural/biologics products accounted for the largest market share.

According to the biosurgery market overview, natural/biologics represent the largest segment due to their effective healing properties and biocompatibility. These products, derived from substances that are naturally present in the human body or other biological sources, include fibrin sealants, collagen-based matrices, and chitosan-based solutions. Additionally, natural/biologics product's ability to mimic natural physiological processes significantly reduces the risk of rejection and adverse reactions, making them highly preferred in surgical procedures. Moreover, market dominance is further supported by advancements in biotechnology that enhance the safety and efficacy of these materials. Consequently, the increasing demand for minimally invasive surgeries, coupled with the growing prevalence of chronic diseases requiring complex surgeries, continues to drive the growth of natural/biologics products in the market.

Breakup by Application:

  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Gynecological Surgery
  • Others

Neurological surgery represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, and others. According to the report, neurological surgery represented the largest segment.

Neurological surgeries are complex and require critical precision. Additionally, biosurgery products, such as sealants, hemostatic agents, and adhesion barriers, are extensively used in neurological procedures to manage bleeding, seal tissues, and reduce post-operative complications. Moreover, the rising prevalence of neurological disorders, such as brain tumors, epilepsy, and Parkinson's disease, coupled with advancements in neurosurgical techniques are escalating the demand in this segment. Besides, the widespread adoption of minimally invasive (MI) surgeries, which require highly effective biosurgical solutions to enhance patient outcomes is further driving the biosurgery market growth. This trend is supported by technological innovations in biosurgery products, aimed at improving surgical outcomes and reducing recovery times.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospital exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals accounted for the largest market share.

Hospitals offer a wide array of surgical procedures that frequently utilize biosurgical products. These products, which include hemostatic agents, surgical sealants, and adhesives, are integral in managing intraoperative and postoperative bleeding and promoting tissue healing. Additionally, hospitals' capacity to handle high patient volumes and conduct complex surgeries increases biosurgery demand. Additionally, the constant advancements in surgical techniques and the increasing preference for minimally invasive surgeries further amplify the utilization of biosurgical solutions in hospital settings.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest biosurgery market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for biosurgery.

North America is the leading region due to the advanced healthcare infrastructure, significant investments in research and development (R&D) activities, and the presence of leading players who drive innovation and expansion. Additionally, the increasing prevalence of chronic diseases and the growing elderly population in North America contribute to a higher demand for biosurgical products. According to the biosurgery market forecast, these factors, combined with favorable government policies and a strong trend toward minimally invasive surgeries, will continue to strengthen North America's leading position in the global biosurgery market.

Competitive Landscape:

  • The biosurgery market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the industry include B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • At present, biosurgery market players are actively enhancing market growth through a combination of strategic collaborations, innovative product launches, and expansions into new geographical markets. These companies invest heavily in research and development (R&D) to introduce advanced products that meet the increasing demands of minimally invasive surgeries and improved wound care. Additionally, market players are focusing on obtaining regulatory approvals across different regions, which helps in expanding their global footprint and accessing new markets. These strategies collectively contribute to the robust growth and resilience of the biosurgery market. For instance, in 2023, AROA Biosurgery Ltd. revealed the release of a new retrospective pilot case series that explores the use of Myriad Matrix and Myriad Morcells in the surgical treatment of contaminated volumetric soft tissue defects. It reviewed 13 complex traumatic wounds in 10 patients at a single facility. The study reported an average time of 23.4+-9.2 days for achieving soft tissue coverage and fill, with a median of one product application and no complications among participants. Moreover, the research focused on injuries from motor vehicle accidents, abdominal dehiscence after hernia repair, Fournier's Gangrene, compartment syndrome, and pressure injuries at a US Level 1 trauma center. It found that the Myriad products facilitated effective soft tissue formation with no reported complications, reinforcing the utility of AROA ECM products in trauma care.

Biosurgery Market News:

  • November 2023, Ethicon, a Johnson & Johnson MedTech company, has announced the approval of ETHIZIA, a hemostatic solution shown to provide effective and lasting control of severe bleeding in challenging situations. This new hemostatic patch enhances Ethicon's extensive biosurgery range and strengthens its capability to meet urgent needs in bleeding control.

Key Questions Answered in This Report:

  • How has the global biosurgery market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global biosurgery market?
  • What is the impact of each driver, restraint, and opportunity on the global biosurgery market?
  • What are the key regional markets?
  • Which countries represent the most attractive biosurgery market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the biosurgery market?
  • What is the breakup of the market based on the source?
  • Which is the most attractive source in the biosurgery market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the biosurgery market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the biosurgery market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global biosurgery market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biosurgery Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Bone-Graft Substitutes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Soft-Tissue Attachments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemostatic Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Surgical Sealants and Adhesives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Adhesion Barriers
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Staple Line Reinforcement
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Natural/Biologics Products
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synthetic Products
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Orthopedic Surgery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 General Surgery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Neurological Surgery
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cardiovascular Surgery
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Gynecological Surgery
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 B. Braun Melsungen AG
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 SWOT Analysis
    • 15.3.2 Baxter International Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CryoLife Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 CSL Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Hemostasis LLC
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Integra Lifesciences Holdings Corporation
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Johnson & Johnson
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Medtronic plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Smith & Nephew plc
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Stryker Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Surgalign Spine Technologies Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials